FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897094821> ?p ?o ?g. }

• W2897094821 endingPage "15" @default.
• W2897094821 startingPage "10" @default.
• W2897094821 abstract "Abstract Aims Heart failure (HF) is a common co‐morbidity in non‐valvular atrial fibrillation (NVAF) patients and a potent risk factor for stroke, bleeding, and a decreased time‐in‐therapeutic range with warfarin. We assessed the real‐world effectiveness and safety of rivaroxaban and warfarin in NVAF patients with co‐morbid HF. Methods and results Using US Truven MarketScan Commercial and Medicare supplemental database claims data from 11/2011 to 12/2016, we identified oral anticoagulant (OAC)‐naïve NVAF patients with HF (International Classification of Diseases, 10th Revision codes of I50 or I09.81) and ≥12 months of insurance coverage prior to the qualifying OAC dispensing. Rivaroxaban users (20 or 15 mg once daily) were 1:1 propensity score matched to warfarin users, with residual absolute standardized differences <0.1 being achieved for all covariates after matching. Patients were followed up until an event, OAC discontinuation/switch, insurance disenrolment, or end of follow‐up. Rates [events per 100 person‐years (PYs) of follow‐up] for stroke or systemic embolism and major bleeding (using the Cunningham algorithm) were compared between the matched cohorts using Cox proportion hazard regression and reported as hazard ratios (HRs) with 95% confidence intervals (CIs). We matched 3418 rivaroxaban (32% receiving the reduced dose) and 3418 warfarin users with NVAF and HF with a median (interquartile range) available follow‐up of 1.4 (0.6, 2.5) years. Median age was 74 (63, 82) years, and median CHA 2 DS 2 ‐VASc and HASBLED scores were 4 (3, 5) and 2 (2, 3). Common HF medications included beta‐blockers (64%), angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers (62%), loop diuretics (46%), digoxin (11%), and aldosterone receptor antagonists (10%). The hazard of developing stroke or systemic embolism (0.98 events/100PY vs. 1.28 events/100PY; HR = 0.82, 95% CI = 0.47–1.44), ischaemic stroke (0.70 events/100PY vs. 1.02 events/100PY; HR = 0.77, 95% CI = 0.41–1.46), or major bleeding (3.86 events/100PY vs. 4.23 events/100PY; HR = 0.98, 95% CI = 0.73–1.31) was not found to be different between rivaroxaban and warfarin users. Intracranial haemorrhage was infrequent in both cohorts and numerically less with rivaroxaban (0.27 events/100PY vs. 0.36 events/100PY; HR = 0.73, 95% CI = 0.25–2.08). Conclusions Effectiveness and safety of rivaroxaban vs. warfarin are sustained in NVAF patients with co‐morbid HF treated in routine practice. The general consistency between this real‐world study and those from phase III randomized trial data of rivaroxaban should provide additional reassurance to clinicians regarding the use of rivaroxaban in NVAF patients with HF." @default.
• W2897094821 created "2018-10-26" @default.
• W2897094821 creator A5005652290 @default.
• W2897094821 creator A5009397280 @default.
• W2897094821 creator A5014756631 @default.
• W2897094821 creator A5034742104 @default.
• W2897094821 creator A5045621916 @default.
• W2897094821 creator A5074035842 @default.
• W2897094821 date "2018-10-09" @default.
• W2897094821 modified "2023-09-26" @default.
• W2897094821 title "Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure" @default.
• W2897094821 cites W1871158536 @default.
• W2897094821 cites W1915329329 @default.
• W2897094821 cites W2036193982 @default.
• W2897094821 cites W2042776560 @default.
• W2897094821 cites W2048943125 @default.
• W2897094821 cites W2062786076 @default.
• W2897094821 cites W2079491969 @default.
• W2897094821 cites W2087316845 @default.
• W2897094821 cites W2097854437 @default.
• W2897094821 cites W2123257771 @default.
• W2897094821 cites W2134884198 @default.
• W2897094821 cites W2152623033 @default.
• W2897094821 cites W2427094903 @default.
• W2897094821 cites W2520047549 @default.
• W2897094821 cites W2612251907 @default.
• W2897094821 cites W2624748638 @default.
• W2897094821 cites W2791453970 @default.
• W2897094821 cites W3004050106 @default.
• W2897094821 doi "https://doi.org/10.1002/ehf2.12365" @default.
• W2897094821 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6352884" @default.
• W2897094821 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30299591" @default.
• W2897094821 hasPublicationYear "2018" @default.
• W2897094821 type Work @default.
• W2897094821 sameAs 2897094821 @default.
• W2897094821 citedByCount "6" @default.
• W2897094821 countsByYear W28970948212019 @default.
• W2897094821 countsByYear W28970948212020 @default.
• W2897094821 countsByYear W28970948212021 @default.
• W2897094821 countsByYear W28970948212022 @default.
• W2897094821 crossrefType "journal-article" @default.
• W2897094821 hasAuthorship W2897094821A5005652290 @default.
• W2897094821 hasAuthorship W2897094821A5009397280 @default.
• W2897094821 hasAuthorship W2897094821A5014756631 @default.
• W2897094821 hasAuthorship W2897094821A5034742104 @default.
• W2897094821 hasAuthorship W2897094821A5045621916 @default.
• W2897094821 hasAuthorship W2897094821A5074035842 @default.
• W2897094821 hasBestOaLocation W28970948212 @default.
• W2897094821 hasConcept C119060515 @default.
• W2897094821 hasConcept C126322002 @default.
• W2897094821 hasConcept C127413603 @default.
• W2897094821 hasConcept C164705383 @default.
• W2897094821 hasConcept C17923572 @default.
• W2897094821 hasConcept C207103383 @default.
• W2897094821 hasConcept C2776301958 @default.
• W2897094821 hasConcept C2778198053 @default.
• W2897094821 hasConcept C2778661090 @default.
• W2897094821 hasConcept C2778715236 @default.
• W2897094821 hasConcept C2779161974 @default.
• W2897094821 hasConcept C2780645631 @default.
• W2897094821 hasConcept C44249647 @default.
• W2897094821 hasConcept C50382708 @default.
• W2897094821 hasConcept C71924100 @default.
• W2897094821 hasConcept C78519656 @default.
• W2897094821 hasConceptScore W2897094821C119060515 @default.
• W2897094821 hasConceptScore W2897094821C126322002 @default.
• W2897094821 hasConceptScore W2897094821C127413603 @default.
• W2897094821 hasConceptScore W2897094821C164705383 @default.
• W2897094821 hasConceptScore W2897094821C17923572 @default.
• W2897094821 hasConceptScore W2897094821C207103383 @default.
• W2897094821 hasConceptScore W2897094821C2776301958 @default.
• W2897094821 hasConceptScore W2897094821C2778198053 @default.
• W2897094821 hasConceptScore W2897094821C2778661090 @default.
• W2897094821 hasConceptScore W2897094821C2778715236 @default.
• W2897094821 hasConceptScore W2897094821C2779161974 @default.
• W2897094821 hasConceptScore W2897094821C2780645631 @default.
• W2897094821 hasConceptScore W2897094821C44249647 @default.
• W2897094821 hasConceptScore W2897094821C50382708 @default.
• W2897094821 hasConceptScore W2897094821C71924100 @default.
• W2897094821 hasConceptScore W2897094821C78519656 @default.
• W2897094821 hasIssue "1" @default.
• W2897094821 hasLocation W28970948211 @default.
• W2897094821 hasLocation W28970948212 @default.
• W2897094821 hasLocation W28970948213 @default.
• W2897094821 hasOpenAccess W2897094821 @default.
• W2897094821 hasPrimaryLocation W28970948211 @default.
• W2897094821 hasRelatedWork W1993190469 @default.
• W2897094821 hasRelatedWork W2003235938 @default.
• W2897094821 hasRelatedWork W2174666533 @default.
• W2897094821 hasRelatedWork W2606162097 @default.
• W2897094821 hasRelatedWork W2883093453 @default.
• W2897094821 hasRelatedWork W2888986290 @default.
• W2897094821 hasRelatedWork W2896204226 @default.
• W2897094821 hasRelatedWork W3028955534 @default.
• W2897094821 hasRelatedWork W4229009061 @default.
• W2897094821 hasRelatedWork W4366351077 @default.
• W2897094821 hasVolume "6" @default.
• W2897094821 isParatext "false" @default.

• next